Cervical Cancer Screening Guidelines for Women Over 30

Standard Screening Protocol

• The National Comprehensive Cancer Network recommends cytology and HPV cotesting every 5 years, with cytology alone every 3 years being an acceptable alternative, for women aged 30-65 years, regardless of prior LSIL history, provided subsequent Pap tests have been normal and adequate time has elapsed 1
• The American College of Obstetricians and Gynecologists and other guideline societies support the use of cytology and HPV cotesting every 5 years as the preferred screening approach for women ≥30 years 1, 3, 4

Clinical Rationale for HPV Testing

• Women ≥30 years with HPV positivity have a higher risk of persistent disease compared to younger women, making HPV testing clinically valuable in this age group 3, 4, 5
• HPV testing combined with cytology increases detection of CIN 3, the immediate precursor to cervical cancer 6
• Among women ≥30 years with normal Pap tests and negative HPV tests, the screening interval can safely be extended to 3 years (or 5 years with cotesting) 3, 4

Important Caveats

• The National Comprehensive Cancer Network recommends against more frequent screening than standard recommendations unless high-risk factors are present, such as history of CIN 2/3 or cervical cancer, immunocompromised status, HIV infection, or in-utero DES exposure 1, 6
• The Centers for Disease Control and Prevention and other guideline societies advise against avoiding HPV testing based on remote LSIL history, as this is not a contraindication to routine cotesting 1, 3, 4